NASDAQ:BLRX
BioLineRx Ltd. Stock News
$0.657
+0.0164 (+2.56%)
At Close: Apr 19, 2024
TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple
BioLineRx's (BLRX) CEO Phil Serlin on Q3 2020 Results - Earnings Call Transcript
12:48pm, Monday, 23'rd Nov 2020
BioLineRx's (BLRX) CEO Phil Serlin on Q3 2020 Results - Earnings Call Transcript
BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:00am, Monday, 23'rd Nov 2020
TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for
BioLineRX News: Why BLRX Stock Is Skyrocketing Today
11:13am, Friday, 30'th Oct 2020
BLRX stock is blasting off on Friday morning after the company reported strong results from a Phase-3 trial for one of its cancer treatments. The post BioLineRX News: Why BLRX Stock Is Skyrocketing To
TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a plan
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
08:48am, Thursday, 29'th Oct 2020
TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug
Turning Point Solid Tumor Data, And Other News: The Good, Bad And Ugly Of Biopharma
08:26am, Saturday, 22'nd Aug 2020
Turning Point reports positive data for tumor drug candidate. BioMarin faces setback for Hemophilia A therapy.
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
11:00am, Wednesday, 19'th Aug 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original planned samp
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
11:00am, Thursday, 06'th Aug 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
11:00am, Friday, 31'st Jul 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended J
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
05:08pm, Friday, 24'th Jul 2020
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
12:43pm, Wednesday, 08'th Jul 2020
Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher
12:50pm, Monday, 06'th Jul 2020
Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
12:53pm, Thursday, 02'nd Jul 2020
Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study
02:21pm, Tuesday, 30'th Jun 2020
CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.
